Next-Generation Obesity Drug Candidate "CT-G32"
Minimizing Muscle Loss While Maximizing Weight Loss
Strategic Partnership with Scohia Pharma in Japan

Celltrion announced on May 29 that it has officially begun toxicology studies of its next-generation obesity drug candidate, CT-G32, in primates, marking the final stage of preclinical development before entering global clinical trials. The company is accelerating development with the goal of submitting an Investigational New Drug (IND) application in the first half of next year.


Celltrion Begins Primate Trials for 'Four-Action' Obesity Drug, Aiming for IND Submission in First Half of Next Year View original image

CT-G32 is a next-generation obesity treatment that acts simultaneously on four targets, including GLP-1 (glucagon-like peptide-1). Celltrion is developing this as a "first-in-class" new drug. The goal is to enhance weight loss efficacy while addressing the limitations of existing GLP-1-based therapies, such as variability in individual patient weight loss, muscle loss, and issues with sustainability.


The global obesity treatment market is projected to grow to over $100 billion in the future, and competition to secure next-generation multi-action mechanisms is intensifying across the global pharmaceutical industry. Celltrion plans to develop CT-G32 not just as a simple weight loss drug but as a metabolic disease platform therapy that regulates overall fat, muscle, and energy metabolism.


This toxicology study evaluates the safety and toxicity profile of CT-G32 in 252 rats and 48 monkeys. It is a key step in determining the appropriate clinical dosing and ensuring safety. Celltrion also plans to further verify pharmacokinetic (PK) and pharmacodynamic (PD) characteristics in addition to toxicology assessment.


In previous separate preclinical studies, CT-G32 demonstrated superior weight loss efficacy at equivalent doses compared to comparator drugs in development, and also showed retention of lean body mass (LBM), including muscle.


Celltrion plans to submit the IND in the first half of next year based on these preclinical data and will begin full-scale global clinical development. The company is also reviewing the potential to expand indications beyond obesity to areas such as diabetes and metabolic dysfunction-associated steatohepatitis (MASH).


Celltrion is pursuing joint development and has established a strategic partnership with Scohia Pharma in Japan. Celltrion will take the lead in all areas of development, including preclinical, clinical, and global commercialization, to further strengthen its competitiveness in the global market.


Meanwhile, alongside the four-action injectable, Celltrion is also developing an oral obesity treatment based on multi-action mechanisms. For the oral treatment, the company is conducting research to improve safety and bioavailability, aiming to submit the IND in the second half of 2028.



A Celltrion official stated, "CT-G32 is being developed as a next-generation new drug that supplements the limitations of existing GLP-1-based therapies and covers metabolic diseases beyond obesity," adding, "Based on the global development and manufacturing capabilities we have secured through our biosimilar business, we will continue to expand our new drug pipeline in areas such as obesity and ADCs to strengthen our long-term growth drivers."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing